Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

  • Showing results for a modified search because your search retrieved no results.
1.

The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.

Cheah CY, Hofman MS, Seymour JF, Ritchie DS, Dickinson M, Wirth A, Prince HM, Wolf M, Januszcewicz EH, Carney DA, Herbert KE, Harrison SJ, Burbury KL, Tam CS.

Leuk Lymphoma. 2015 Jan;56(1):49-56. doi: 10.3109/10428194.2014.910656.

PMID:
24724780
2.

The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.

Nagle SJ, Chong EA, Chekol S, Shah NN, Nasta SD, Glatstein E, Plastaras JP, Torigian DA, Schuster SJ, Svoboda J.

Cancer Med. 2015 Jan;4(1):7-15. doi: 10.1002/cam4.322.

3.

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL.

J Nucl Med. 2011 Mar;52(3):386-92. doi: 10.2967/jnumed.110.082586.

4.

Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy.

Goldschmidt N, Kleinstern G, Orevi M, Paltiel O, Ben-Yehuda D, Gural A, Libster D, Lavie D, Gatt ME.

Cancer Chemother Pharmacol. 2016 May;77(5):1053-60. doi: 10.1007/s00280-016-3024-8.

PMID:
27056383
6.

18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.

Kahraman D, Theurich S, Rothe A, Kuhnert G, Sasse S, Scheid C, Dietlein M, Drzezga A, von Bergwelt-Baildon M, Kobe C.

Leuk Lymphoma. 2014 Apr;55(4):811-6. doi: 10.3109/10428194.2013.819575.

PMID:
23805904
7.

[Primary mediastinal B-cell lymphoma].

Coso D, Rey J, Bouabdallah R.

Rev Pneumol Clin. 2010 Feb;66(1):32-5. doi: 10.1016/j.pneumo.2009.12.007. Review. French.

PMID:
20207294
8.

Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.

Filippi AR, Piva C, Giunta F, Bellò M, Chiappella A, Caracciolo D, Zotta M, Douroukas A, Ragona R, Vitolo U, Bisi G, Ricardi U.

Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):311-6. doi: 10.1016/j.ijrobp.2013.05.053.

PMID:
23916170
9.

Using PET-CT in the restaging of primitive mediastinal B-cell lymphoma (PMBCL) after chemotherapy: which criteria should we use?

Giunta F, Zotta M, Menga M, Balma M, Bellò M, Passera R, Filippi AR, Chiappella A, Ladetto M, Ricardi U, Vitolo U, Bisi G.

Q J Nucl Med Mol Imaging. 2015 Jun;59(2):214-9.

PMID:
25669764
10.

Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?

Kedmi M, Avivi I, Ribakovsky E, Benyamini N, Davidson T, Goshen E, Tadmor T, Nagler A, Avigdor A.

Leuk Lymphoma. 2014 Nov;55(11):2484-9. doi: 10.3109/10428194.2014.882506.

PMID:
24432895
12.

Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.

Carrillo-Cruz E, Marín-Oyaga VA, Solé Rodríguez M, Borrego-Dorado I, de la Cruz Vicente F, Quiroga Cantero E, Manzanares Pérez M, Capote FJ, Ramírez Sánchez MJ, Espigado Tocino I, Pérez-Vega H, Vázquez-Albertino R, Pérez-Simón JA.

Eur J Haematol. 2015 Jan;94(1):23-30. doi: 10.1111/ejh.12284.

PMID:
24520874
13.

Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.

Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ.

J Clin Oncol. 2007 Sep 1;25(25):3902-7.

PMID:
17664458
14.

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L.

Blood. 2006 Jan 1;107(1):52-9.

15.

The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma.

Ustaalioglu BB, Seker M, Bilici A, Canpolat N, Yıldirim E, Kefeli U, Ustaalioglu R, Yilmaz BE, Salepci T, Ozdemir N, Gumus M.

Med Oncol. 2011 Mar;28(1):258-64. doi: 10.1007/s12032-010-9446-y.

PMID:
20155405
16.

Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma.

Mylam KJ, El-Galaly TC, Hutchings M, Brown P, Himmelstrup B, Gerke O, Gillstrøm D, Sillesen IB, Munksgaard L, Pedersen BB, Christiansen I, Jensen P, Nielsen AL, Pedersen LM.

Leuk Lymphoma. 2014 Jul;55(7):1563-9. doi: 10.3109/10428194.2013.850165.

PMID:
24144339
17.

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, Eriksson M, Gillstrøm D, Hansen PB, Seppänen M, Hjorthaug K, Brown Pde N, Pedersen LM.

Leuk Lymphoma. 2015 Jul;56(7):2005-12. doi: 10.3109/10428194.2014.975800.

PMID:
25330442
18.

Clinical use of combined positron emission tomography and computed tomography in thymoma recurrence.

El-Bawab HY, Abouzied MM, Rafay MA, Hajjar WM, Saleh WM, Alkattan KM.

Interact Cardiovasc Thorac Surg. 2010 Oct;11(4):395-9. doi: 10.1510/icvts.2010.236273.

PMID:
20639307
19.

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

Kasamon YL, Wahl RL, Ziessman HA, Blackford AL, Goodman SN, Fidyk CA, Rogers KM, Bolaños-Meade J, Borowitz MJ, Ambinder RF, Jones RJ, Swinnen LJ.

Biol Blood Marrow Transplant. 2009 Feb;15(2):242-8. doi: 10.1016/j.bbmt.2008.11.026.

20.

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, Thomas J, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.

Blood. 2003 Jul 1;102(1):53-9.

Supplemental Content

Support Center